For the second time this month, there's promising news from a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the U.S. and around the world.

Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from the company’s still ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the U.S.

Dr. Stephen Hoge, Moderna’s president, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.

“That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” Hoge told The Associated Press.

“It won’t be Moderna alone that solves this problem. It’s going to require many vaccines” to meet the global demand, he added.

A vaccine can’t come fast enough, as virus cases topped 11 million in the U.S. over the weekend — 1 million of them recorded in just the past week. The pandemic has killed more than 1.3 million people worldwide, more than 245,000 of them in the U.S.

Still, if the Food and Drug Administration allows emergency use of Moderna’s or Pfizer’s candidates, there will be limited, rationed supplies before the end of the year. Both require people to get two shots, several weeks apart. Moderna expects to have about 20 million doses, earmarked for the U.S., by the end of 2020. Pfizer and its German partner BioNTech expect to have about 50 million doses globally by year’s end.

Moderna’s vaccine, created with the National Institutes of Health, is being studied in 30,000 volunteers who received either the real vaccination or a dummy shot. On Sunday, an independent monitoring board broke the code to examine 95 infections that were recorded starting two weeks after volunteers' second dose — and discovered all but five illnesses occurred in participants who got the placebo.

The study is continuing, and Moderna acknowledged the protection rate might change as more COVID-19 infections are detected and added to the calculations. Also, it’s too soon to know how long protection lasts. Both cautions apply to Pfizer’s vaccine as well.

But Moderna’s independent monitors reported some additional, promising tidbits: All 11 severe COVID-19 cases were among placebo recipients, and there were no significant safety concerns.

The main side effects were fatigue, muscle aches and injection-site pain after the vaccine’s second dose, at rates that Hoge characterized as more common than with flu shots but on par with others such as shingles vaccine.

Moderna shares rocketed higher on the announcement and appeared to be headed for an all-time high Monday. The Cambridge, Massachusetts, company's vaccine is among 11 candidates in late-stage testing around the world, four of them in huge studies in the U.S.

Both Moderna's shots and the Pfizer-BioNTech candidate are so-called mRNA vaccines, a brand-new technology. They aren’t made with the coronavirus itself, meaning there’s no chance anyone could catch it from the shots. Instead, the vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.

The strong results were a surprise. Scientists have warned for months that any COVID-19 shot may be only as good as flu vaccines, which are about 50% effective.

Another steep challenge: distributing doses that must be kept very cold. Both the Moderna and Pfizer shots are frozen but at different temperatures. Moderna announced Monday that once thawed, its doses can last longer in a refrigerator than initially thought, up to 30 days. Pfizer's shots require long-term storage at ultra-cold temperatures.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Elizabeth Holmes Awaits Jury's Verdict in Day 6 of Deliberations
Jurors in the trial against Theranos CEO Elizabeth Holmes have entered day six of deliberations. Holmes is accused of lying to investors about the functionality of a newly developed blood-testing technology. Andrew George, partner at Baker Botts, joined Cheddar to break down key points in the case and what the jury might be considering during their deliberations. He also noted that the rest of Silicon Valley, including Holmes' business partner, Ramesh "Sunny" Balwani, who is facing identical charges, is closely watching the outcome of deliberations — as it could set the tone for future regulations and Balwani's own trial.
Wildfires Out In The West Impacting California's Carbon Cap-and-Trade Program
According to researchers, the state of California's cap-and-trade program is currently being undermined by forest fires caused primarily by climate change. Over the past few years, trees that were set aside for the program have been releasing carbon as they continue to burn in fires. Climate Researcher and Policy Director at CarbonPlan Danny Cullenward, joined Cheddar to discuss more.
How the CDC Decided to Shorten COVID Quarantines
The CDC's latest update to its COVID-19 quarantine guidelines reduces the isolation period from ten days to just five for people who test positive but are asymptomatic. Dr. Bayo Curry-Winchell, regional clinical director at Carbon Health, spoke to Cheddar's Baker Machado about the new guidance. She noted that while the reduced quarantine time "makes sense," the CDC should also require that a person test negative after their quarantine and before interacting with the public. "There is science behind it. We know that the majority of illness happens, or transmission, one to two days before the onset of symptoms and then two to three days as you have symptoms. So there is science behind the reducement of the actual five days," she said.
Gas Prices to Rise in 2022 amid Soaring Demand, Omicron Spread
Prices at the pump this year reached a seven-year high, and a new forecast from GasBuddy shared with CNN predicts that gas prices will only continue to rise in 2022 and that the national average could even reach $4.00 a gallon; however, analysts at GasBuddy say anything could happen when it comes to gas prices in the future, as the pandemic has made it difficult to make any predictions about the economy. Consumer Energy Alliance federal policy advisor Michael Zehr joins Cheddar News' Closing Bell to discuss.
School Districs Face Difficult Choices as Virus Surges
As the Omicron variant is fueling a surge in COVID-19 cases, parents and schools are faced with tough choices between absences and outbreaks. Matt Barnum, a national reporter at Chalkbeat, joins Cheddar News to discuss.
New COVID-19 Cases in U.S. Hit Highest Numbers Since January
As 2021 winds down, the number of positive COVID-19 cases has surged dramatically with numbers not seen since the heights of the pandemic. Dr. Laolu Fayanju, the regional medical director at primary care provider Oak Street Health, joined Cheddar to discuss the numbers, how the healthcare system is handling the surge this time around, and what it means that the CDC just cut the quarantine time guideline in half for those who are infected. "These are incredibly high numbers because they reflect the transmissibility of the omicron variant," Fayanju said.
Load More